Artivion Q3FY26 Results: Revenue up 9% YoY, EBITDA declines 8%
Artivion Inc. reported a 9% year-over-year revenue increase to $123.8 million in Q3 FY26, but adjusted EBITDA declined 8% to $22.5 million due to higher operating costs and manufacturing investments. Gross margins contracted to 61.4%, reflecting an unfavorable product mix and early-stage costs at new facilities. The company narrowed its full-year 2026 revenue guidance to 8-10% growth and expects adjusted EBITDA between $93 million and $98 million, with negative free cash flow driven by milestone payments and integration expenses.
Artivion earnings beat by $0.14, revenue topped estimates
Artivion (NYSE: AORT) reported strong third-quarter results, surpassing analyst estimates with EPS of $0.08 against an expected $-0.06 and revenue of $123.8M compared to a consensus of $121.29M. The company also provided FY 2026 revenue guidance between $484.00M and $492.00M. Despite the positive earnings, Artivion's stock has seen declines over the past three and twelve months.
Artivion (AORT) to report earnings tomorrow: here is what to expect
Artivion (AORT) is set to announce its earnings results, with analysts expecting a 6.8% year-on-year revenue growth. The medical device company previously surpassed revenue and EPS estimates, though it has missed Wall Street's revenue forecasts multiple times in the last two years. Investor sentiment in the healthcare equipment and supplies segment has been positive, with Artivion's shares up 4.9% over the past month.
Artivion to Participate in Upcoming Investor Conferences
Artivion, Inc. (NYSE: AORT) announced its participation in two upcoming investor conferences in November 2026. The company's management team will present at the Stifel 2026 Healthcare Conference on November 10th and the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 11th. Live webcasts of both presentations will be available on Artivion's Investors page.
Artivion to present at two major healthcare investor conferences in November 2026
Artivion, a company specializing in cardiac and vascular surgery for aortic disease, will present at two healthcare investor conferences in November 2026: the Stifel 2026 Healthcare Conference and the 20th Annual Canaccord Genuity MedTech Forum. These presentations will be webcast live and archived, offering investors direct updates from management. The article also provides a market snapshot of the health sector, highlighting notable stock movers.
Artivion will present in New York on consecutive days, Nov. 10 and 11.
Artivion (NYSE: AORT) announced its participation in two upcoming investor conferences in New York: the Stifel 2026 Healthcare Conference on November 10, 2026, and the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 11, 2026. Management will present at both events, with live webcasts available on Artivion's Investors page and replays for 90 days. The company, headquartered in suburban Atlanta, focuses on medical devices for cardiac and vascular surgery.
BlackRock updates its Artivion (AORT) stake; an iShares ETF has an interest above 5%.
BlackRock, Inc. reported a beneficial ownership of 7,159,279 common shares in Artivion (AORT), representing 14.7% of the company's outstanding stock as of September 30, 2026. This disclosure, made via an amended SCHEDULE 13G/A filing, indicates BlackRock's sole voting power over 7,073,216 shares and sole dispositive power over all 7,159,279 shares. Notably, the iShares Core S&P Small-Cap ETF, an affiliate of BlackRock, was identified as holding an interest exceeding 5% of Artivion's common stock.
Artivion (AORT) Could Be 43% Undervalued On Strong Q2 Results And Mixed Guidance
Artivion (AORT) is being considered undervalued by 43% according to Simply Wall St, despite mixed Q2 results and guidance. The company reported stronger than expected revenue and adjusted EBITDA, driven by product adoption, but its full-year outlook is the weakest among peers. The fair value estimate of $42 per share, compared to the current $23.97, suggests significant upside potential, though execution risks remain.
Artivion, Inc. Estimates – NYSE:AORT
This page on TradingView provides financial data and analyst estimates for Artivion, Inc. (NYSE: AORT). It allows users to explore reported financial data and analyst projections across income statements, balance sheets, cash flow statements, and valuation metrics, enabling comparison of actual results with average, high, and low estimates. The platform also visualizes trends over time for the company.
Artivion, Inc. (AORT) Stock forecasts
Argus has lowered its target price for Artivion, Inc. (AORT) stock to $19.00. Artivion Inc. provides various aortic-centric solutions to cardiac and vascular surgeons, including heart valves, allografts, and surgical adhesives. The current price of AORT is $23.46.
ARTIVION, INC. : JEFFERIES INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $31
Jefferies has initiated coverage on Artivion, Inc. with a Buy rating and set a price target of $31. This positive outlook from Jefferies suggests confidence in the company's future performance.
Jefferies Initiates Artivion(AORT.US) With Buy Rating, Announces Target Price $31
Jefferies has initiated coverage of Artivion (AORT.US) with a Buy rating. The firm has set a target price of $31 for the company's stock. This initiation suggests a positive outlook from Jefferies on Artivion's future performance.
Jefferies initiates Artivion stock coverage with buy rating on product launches
Jefferies has initiated coverage on Artivion Inc. (NYSE:AORT) with a Buy rating and a $31.00 price target, anticipating significant growth from its aortic surgical product portfolio and new product launches like AMDS and Nexus. The firm projects double-digit sales growth and margin expansion, with revenue reaching $547 million in 2027 and $617 million in 2028, surpassing consensus estimates. Despite the stock being considered overvalued by InvestingPro analysis, Jefferies sees its current trading multiple as an attractive entry point, forecasting profitability this year.
Jefferies initiates Artivion stock coverage with buy rating on product launches
Jefferies has initiated coverage on Artivion Inc. (NYSE:AORT) with a Buy rating and a $31.00 price target, anticipating robust growth from the company's aortic surgical product portfolio and new product launches like AMDS and Nexus. The firm projects double-digit sales growth and margin expansion, with revenue reaching $547 million in 2027 and $617 million in 2028, surpassing consensus estimates. Despite InvestingPro suggesting the stock is currently overvalued, Jefferies sees the current trading multiple of 12 times EBITDA as an attractive entry point.
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
Artivion, Inc. (AORT) announced that its third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. The company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day to discuss these results, followed by a Q&A session. Details for accessing the live call, replay, and earnings press release are provided for investors.
Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’
Artivion Inc. (NYSE:AORT) shares rose after Jefferies initiated coverage with a Buy rating and a $31 price target, citing the company's strong product pipeline and potential for double-digit revenue growth. The analyst highlighted the upcoming U.S. adoption of AMDS hybrid prosthesis and Nexus endovascular stent graft as key drivers. Jefferies sees Artivion's current valuation as an attractive entry point ahead of these commercial catalysts.
Transcript: Artivion Q2 2026 Earnings Conference Call
Artivion reported a 9% increase in total constant-currency revenue and 7% growth in adjusted EBITDA for Q2 2026, driven by strong performance in On-X and stent grafts. The company received FDA approval for the PMA of the AMDS hybrid prosthesis and completed the acquisition of Endospan, enhancing its aortic arch portfolio. Artivion maintains its full-year 2026 guidance of 7% to 11% revenue growth and expects adjusted EBITDA between $92 million to $99 million, with a full U.S. commercial launch of the NEXUS Aortic Arch stent graft system planned for January 2027.
Artivion, Inc. (AORT) Stock Forecasts
Artivion Inc. (AORT) received a target price reduction to $20.00 from Argus as of October 7, 2026. The company provides a range of aortic-centric solutions, including heart valves and surgical adhesives, for cardiac and vascular surgeons. The current stock price for AORT is $21.26.
Diluted shares outstanding of Artivion, Inc. – HAN:CYL
This article provides financial information for Artivion, Inc. (HAN:CYL), specifically focusing on its diluted shares outstanding. The content is primarily a data placeholder from TradingView, indicating that specific value and change data for diluted shares outstanding would be displayed for various periods.
Total equity of Artivion, Inc. – HAN:CYL
The article focuses on the total equity information for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content also briefly lists the various data providers and copyright information relevant to the financial data presented.
Artivion, Inc. Statistics – HAN:CYL
This page provides financial statistics for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It offers an overview of key financial ratios and metrics, including valuation, profitability, liquidity, solvency, and per-share metrics, with data available annually and quarterly from 2006 to 2025.
Basic earnings per share (basic EPS) of Artivion, Inc. – HAN:CYL
This article provides financial information for Artivion, Inc. (HAN:CYL) on the Hannover Stock Exchange, specifically focusing on its basic earnings per share (basic EPS). It presents an overview of the company's financials without detailed figures in the provided content. The piece highlights that the market for this stock is currently closed with no trades.
Artivion, Inc. Cash Flow – HAN:CYL
This article provides a financial overview of Artivion, Inc. (CYL) focusing on its cash flow activities. It highlights the free cash flow for Q2 2026 as -10.52M EUR, with 2025 figures for free cash flow at 714.34K EUR and operating cash flow at 33.95M EUR. The content is primarily a data presentation, indicating the company's financial performance in terms of operating, investing, and financing cash flows.
Artivion, Inc. Revenue Breakdown – NYSE:AORT
Artivion, Inc. (NYSE: AORT) reported a total revenue of $441.33 million USD last year. The Medical Devices segment was the top performer, contributing $345.82 million USD, an increase from $290.23 million USD the prior year. Geographically, the United States was the largest revenue generator, accounting for $214.07 million USD.
CCORF Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $39
CCORF has reiterated its Buy rating for Artivion (AORT.US) and maintained a target price of $39. This suggests continued confidence in the company's performance and future outlook from the firm.
Artivion, Inc. (AORT) stock price, news, quote and history
Artivion, Inc. (AORT) stock showed a slight increase after hours, following a dip at market close on September 25th. The company, which specializes in medical devices and implantable human tissues, has seen significant price fluctuations over various periods. Analyst ratings indicate a strong buy consensus with a target price of $42.15.
AMDS Approval Could Be A Big Test For Artivion Stock (AORT)
Artivion (AORT) recently reported 11% Q2 2026 revenue growth but a net loss of US$13.5 million, despite securing FDA approval for its AMDS Hybrid Prosthesis and completing the Endospan acquisition. The company now boasts a complete aortic arch portfolio, but full-year revenue guidance reiteration highlights ongoing cost and profitability challenges. The investment narrative hinges on whether new products like AMDS can drive profitability and physician adoption without further margin erosion.
Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem
Artivion Inc. (AORT) reported strong Q2 2026 revenue growth of 11% and completed its aortic arch portfolio, yet simultaneously posted a net loss of $13.5 million, a significant reversal from the previous year's profit. The company's acquisitions and FDA approvals, while bolstering its product lineup, are currently impacting profitability, leading to a reiterated rather than raised full-year guidance. This divergence between revenue growth and widening losses is creating uncertainty for investors, with a notable pullback in hedge fund holdings.
Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem
Artivion Inc. reported strong revenue growth of 11% in Q2 2026, driven by key acquisitions and FDA approvals for its aortic arch portfolio. However, this growth was overshadowed by a significant net loss of $13.5 million, a reversal from a profit in the prior year, and a decline in non-GAAP net income. The article highlights the challenge for investors to reconcile the company's expanding product line with its deteriorating profitability, as institutional conviction shows a slight pullback and the forward P/E suggests market uncertainty regarding its earnings recovery.
Artivion SVP Andrew Green sells $286k in company shares By Investing.com
Artivion's Senior Vice President of Regulatory and Quality, Andrew M. Green, sold 11,480 shares of company stock for a total of $286,655 on September 10, 2026. This insider sale occurred as Artivion's stock has declined 45% year-to-date and is considered overvalued by InvestingPro analysis, despite analysts predicting profitability this year and the company reporting strong Q2 revenue.
Artivion SVP Andrew Green sells $286k in company shares
Andrew M. Green, SVP of Regulatory and Quality at ARTIVION, INC. (NASDAQ:AORT), sold 11,480 shares for $286,655 on September 10, 2026, retaining 40,160 shares. This transaction occurred as the stock declined 45% year-to-date, trading at $25.08. Separately, Artivion reported strong Q2 revenues exceeding forecasts and received a raised price target from Canaccord Genuity following recent acquisitions and growth.
Artivion SVP Andrew Green sells $286k in company shares By Investing.com
Andrew M. Green, Senior Vice President at ARTIVION, INC. (NASDAQ:AORT), sold 11,480 shares of company stock for a total of $286,655. This transaction occurred as Artivion's stock has declined 45% year-to-date and is considered overvalued by InvestingPro analysis, despite analyst predictions of profitability this year. The company recently reported strong Q2 revenue, exceeding Wall Street forecasts, and had its price target raised by Canaccord Genuity.
Artivion (NYSE: AORT) officer may sell $177K in stock
Artivion (AORT) officer Andrew M. Green has filed a Rule 144 notice indicating his intent to sell up to 6,510 shares of common stock, valued at approximately $177,497.82. These shares are linked to restricted stock vesting events scheduled for November 2025. The filing also reports Green's prior sales of Artivion stock within the last three months.
Planned insider stock sales at Artivion (NYSE: AORT) raise a new question: how many shares could be sold this time?
An Artivion, Inc. officer, Andrew M. Green, has filed a Rule 144 notice indicating planned sales of 11,480 common shares tied to compensation vesting and previous 2026 sales. The filing details prior sales by Green and outlines upcoming share vestings in February 2026. Fidelity Brokerage Services LLC is managing these transactions as attorney-in-fact for Mr. Green.
Artivion (NYSE: AORT) officer to sell about $199K in stock
An officer at Artivion (NYSE: AORT), Marshall S. Stanton, plans to sell 7,400 shares of common stock valued at approximately $198,694.54. This sale, disclosed in a Form 144 SEC filing, includes shares acquired through an ESPP purchase and restricted stock vesting. Fidelity Brokerage Services LLC is facilitating the transaction as attorney-in-fact and broker.
Artivion Inc (AORT) Insider Sell: SVP, Regulatory and Quality Andrew Green Disposes of 8,003 Shares
Andrew Green, SVP of Regulatory and Quality at Artivion Inc (AORT), sold 8,003 shares of the company on September 3, 2026, totaling approximately $216,321. This sale contributes to a pattern of 45 insider sells and zero buys at Artivion over the past year. While GuruFocus's GF Value indicates the stock is modestly undervalued, the consistent insider selling suggests caution for investors despite the valuation signal.
Artivion SVP Andrew Green sells $216k in stock By Investing.com
Andrew M. Green, Senior Vice President of Regulatory and Quality at ARTIVION, INC. (NASDAQ:AORT), sold $216,337 worth of company common stock in early September 2026 across two transactions. Following these sales, Mr. Green directly holds 51,640 shares. Artivion recently reported strong Q2 revenue and adjusted EBITDA, exceeding analyst forecasts, and received a raised price target from Canaccord Genuity.
Artivion (NYSE: AORT) insider logged a 44,001-share sale and now plans more trades
Artivion (AORT) officer Andrew M. Green has filed a Rule 144 notice to sell 1,493 shares of common stock, valued at $38,842.13, through Fidelity Brokerage Services LLC. These shares are linked to restricted stock awards vesting in November 2025 and February 2026. The filing also revealed that Green previously sold 44,001 shares for $910,753.51 on June 11, 2026, and additional shares in August and September 2026.
Trading the Move, Not the Narrative: (AORT) Edition
This article provides an AI-driven analysis for Artivion Inc Com (NASDAQ: AORT), highlighting near-term weak sentiment and an exceptional 89.1:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis. The report suggests potential for long-term weakness resumption after a neutral shift and emphasizes a mid-channel oscillation pattern.
Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales
Artivion (AORT) stock has seen a 57.6% gain over three years, but current valuations suggest it's close to its intrinsic value, not a clear bargain. Both Discounted Cash Flow (DCF) and price-to-sales (P/S) models indicate the stock is broadly in line with fundamentals, with the DCF showing only a 1.5% discount and the P/S ratio being slightly above the model's fair range. The article concludes that the stock's future performance hinges on consistent execution and cash generation to justify its current pricing, as there's little valuation buffer for disappointment.
Have Artivion Insiders Been Selling Stock?
Artivion (NYSE:AORT) recently saw its Chairman, James Mackin, sell approximately US$2.0m worth of shares, reducing his holding by 7.4%. While this was the largest insider sale in the last year, insiders still maintain 5.1% ownership, valued at US$70m. The article notes that there have been no insider purchases in the last year, suggesting caution for potential investors.
Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock
Artivion's CEO, James Mackin, sold 70,000 shares of company stock for $2.03 million, reducing his ownership by 7.39%. This transaction follows the company's recent earnings report where it exceeded revenue expectations with $125.76 million. Despite the insider selling, analysts maintain a "Moderate Buy" rating for AORT, with an average price target of $44.83.
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion, Inc. reported increased revenue for Q2 2026 and H1 2026, but also experienced a swing from net income to net losses. This shift raises questions about the company's ability to convert revenue growth into sustainable profits, despite the recent FDA approval for its AMDS product, which represents a significant market opportunity. The article suggests investors consider multiple future scenarios for Artivion, given its growing debt and recent unprofitability.
Artivion (NASDAQ: AORT) executive moves to sell 70,000 shares
Artivion (NASDAQ: AORT) officer James P. Mackin has filed a Form 144 notice to sell up to 70,000 shares of common stock, with an aggregate market value of $2,053,100.00. The shares, originally compensation for services, are intended to be sold through Fidelity Investments on the NYSE. The filing indicates a neutral impact and sentiment on the company's stock.
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion (AORT) reported increased second-quarter 2026 revenue but a shift from net income to a net loss, raising questions about its investment narrative. While the FDA approval for its AMDS product in a significant market segment supports growth, the company faces challenges with rising costs, debt, and the need to convert regulatory success into profitable sales. The article examines how the revenue growth amid new losses affects Artivion's future outlook and current valuation.
Summit Creek Advisors LLC Takes Position in Artivion, Inc. $AORT
Summit Creek Advisors LLC has acquired a new stake of 120,354 shares in Artivion, Inc. worth approximately $2.7 million, representing a 0.25% ownership. Institutional investors and hedge funds now collectively own 86.37% of the company, which maintains a "Moderate Buy" consensus rating from analysts with an average price target of $44.83. Artivion recently exceeded revenue expectations, reporting $125.76 million against an estimate of $119.99 million, and earnings of $0.13 per share.
Canaccord raises Artivion stock price target to $40 on model update
Canaccord Genuity has increased its price target for Artivion Inc. (NYSE:AORT) to $40 from $39, maintaining a Buy rating. This adjustment follows a model update reflecting additional data from the company's Q2 10-Q filing and a change in the comparable company group multiple. Artivion recently reported strong Q2 revenues and adjusted EBITDA, exceeding analyst forecasts, and has received PMA approval for AMDS and completed the acquisition of Endospan.
Artivion SVP Andrew Green sells $17,586 of common stock
Artivion (AORT) SVP Andrew M. Green sold $17,586 worth of common stock on August 14, 2026, consisting of 616 shares at $28.549 each. This was a non-discretionary transaction to cover tax withholding obligations from vested restricted stock units. Following the sale, Green directly holds 59,643 shares, while the company has recently reported strong Q2 earnings, exceeding analyst forecasts, and received a raised price target from Canaccord.
Artivion EVP, COO, CFO & treasurer Berry sells $20,412 in stock
Lance A. Berry, EVP, COO, CFO, and Treasurer of Artivion, Inc. (NASDAQ:AORT), sold 715 shares of common stock for $20,412 on August 14, 2026, to cover tax withholding obligations. This transaction is considered a "sell to cover" and not a discretionary sale, with Berry retaining 210,112 shares. Artivion recently reported strong Q2 2026 revenue of $125.8 million, surpassing forecasts, and Canaccord raised its price target for the company to $39.
Artivion EVP, COO, CFO & treasurer Berry sells $20,412 in stock
Lance A. Berry, EVP, COO, CFO, and Treasurer of ARTIVION, INC. (NASDAQ:AORT), sold 715 shares of common stock totaling $20,412 on August 14, 2026, to cover tax withholding obligations. Following the transaction, Berry directly holds 210,112 shares. Separately, Artivion reported strong Q2 revenue and adjusted EBITDA, surpassing analyst expectations, and received a raised price target from Canaccord.